Europe Companion Diagnostics Global Market Report 2022-2028: Commercial Success of Precision Medicine Treatment Drives Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Oct 3, 2022--

The "Europe Companion Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Market Outlook

The publisher's report infers that the companion diagnostics market in Europe is deemed to advance at a CAGR of 12.61% in value during the forecast years 2022-2028. Italy, Spain, France, Germany, Poland, the United Kingdom, and the Rest of Europe are evaluated in the market report.

In France, the majority of the population is supported by statutory health insurance overseen by the Haute Autorite de Sante (HAS). In this regard, the national healthcare system in the country is considered to be considerate as it aims to reduce healthcare expenditure. The reduction in healthcare expenditure will ultimately reduce excess government spending. Due to high reimbursement coverage, the penetration of CDx is high in the country. Thus, such developments support the companion diagnostics market's growth across the country.

Furthermore, Spain has been witnessing economic restraints over the past few years. This has made it imperative to reduce healthcare expenses. In this regard, CDx is executed in the outpatient hospital site. On the other hand, hospitals directly negotiate with the manufacturer. The hospital funding system relies on the global budget since reimbursement coding is unavailable for CDx. Nevertheless, the rising efforts to reduce healthcare expenses will increase the need for cost-effective technologies for diagnostics, opening new avenues for the market.

Market Dynamics

Market Drivers

• Increase in Incidence of Medication Reactions
• Increasing Prevalence of Cancer Cases and Fatalities
• Rising Prevalence of Precision Medicines

Market Challenges

• Weak Reimbursement Framework
• Common Cases of Leakage in Oncology Companion Diagnostics

Market Opportunity

• Ongoing Research and Investments in Next Generation Gene-Sequencing

   

Key Topics Covered:

1. Europe Companion Diagnostics Market - Summary

2. Industry Outlook

3. Europe Companion Diagnostics Market Outlook - by Mechanism

4. Europe Companion Diagnostics Market Outlook - by Indicator

5. Europe Companion Diagnostics Market Outlook - by Consumer

6. Europe Companion Diagnostics Market Outlook - by Commodity

7. Europe Companion Diagnostics Market - Country Outlook

8. Competitive Landscape

9. Research Methodology & Scope

Companies Mentioned

• Abbott Laboratories
• Almac Group
• Arup Laboratories
• Biocartis
• Biomerieux
• Danaher Corporation
• GE Healthcare
• Genomic Health
• Illumina Inc
• Myriad Genetics
• Qiagen
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific
• Agilent

For more information about this report visit https://www.researchandmarkets.com/r/ly0874.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221003005910/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: EUROPE

INDUSTRY KEYWORD: GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2022.